EGFR and metastatic colorectal cancer: Since 2004, numerous studies have demonstrated the efficiency of monoclonal antibodies (mAbs) targeting the epidermal growth factor receptor (EGFR) ectodomain, such as cetuximab and panitumumab, in patients with metastatic colorectal cancer (MCRC).